Guillaume Courbon

Guillaume Courbon

Auto-generated profile, based on publicly available information

Guillaume Courbon

Inserm U1059 Sainbiose, University of St Etienne, St Etienne, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Blood
Verified
Journal Article
Open access
PDF file
GCGuillaume Courbon
Guillaume Courbon
JTJane Joy Thomas
Jane Joy Thomas
MCMarta Martinez Calle
Marta Martinez Calle
XWXueyan Wang
Xueyan Wang
JSJadeah Spindler
Jadeah Spindler
VDValentin David
Valentin David
Inflammation leads to functional iron deficiency, by increasing the expression of the hepatic iron regulatory peptide, hepcidin. Inflammation also stimulates fibroblast growth factor 23 (FGF23) production by increasing both Fgf23 transcription and FGF23 cleavage, which paradoxically leads to excess in C-terminal FGF23 peptides (Cter-FGF23), rather than intact hormone (iFGF23). We determined that the major source of Cter-FGF23 are the osteocytes and investigated whether Cter-FGF23 peptides play a direct role in the regulation of hepcidin and iron metabolism in response to acute inflammation. Mice harboring an osteocyte-specific deletion of Fgf23 showed a ~90% reduction in Cter-FGF23 levels during acute inflammation. Reduction in Cter-FGF23 led to a further decrease in circulating iron in inflamed mice due to excessive hepcidin production. We observed similar results in mice showing impaired FGF23 cleavage due to osteocyte-specific deletion of Furin. We next showed that Cter-FGF23 peptides bind members of the bone morphogenic protein (BMP) family, BMP2 and BMP9, which are established inducers of hepcidin. Co-administration of Cter-FGF23 and BMP2 or BMP9 prevented the increase in Hamp mRNA and circulating hepcidin levels induced by BMP2/9, resulting in normal serum iron levels. Finally, injection of Cter-FGF23 in inflamed Fgf23KO mice and genetic overexpression of Cter-Fgf23 in WT mice also resulted in lower hepcidin and higher circulating iron levels. In conclusion, during inflammation, bone is the major source of Cter-FGF23 secretion and independently of iFGF23, Cter-FGF23 reduces BMP-induced hepcidin secretion in the liver.

2 December 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RTRatnakar Tiwari
Ratnakar Tiwari
RSRajni Sharma
Rajni Sharma
GRGaneshkumar Rajendran
Ganeshkumar Rajendran
GBGabriella S. Borkowski
Gabriella S. Borkowski
SASi Young An
Si Young An
PKPinelopi Kapitsinou
Pinelopi Kapitsinou
Ischemic acute kidney injury (AKI) is common in hospitalized patients and increases the risk for chronic kidney disease (CKD). Impaired endothelial cell (EC) functions are thought to contribute in AKI to CKD transition, but the underlying mechanisms remain unclear. Here, we identify a critical role for endothelial oxygen sensing prolyl hydroxylase domain (PHD) enzymes 1–3 in regulating postischemic kidney repair. In renal endothelium, we observed compartment-specific differences in the expression of the 3 PHD isoforms in both mice and humans. Postischemic concurrent inactivation of endothelial PHD1, PHD2, and PHD3 but not PHD2 alone promoted maladaptive kidney repair characterized by exacerbated tissue injury, fibrosis, and inflammation. scRNA-Seq analysis of the postischemic endothelial PHD1, PHD2, and PHD3-deficient (PHD TiEC ) kidney revealed an endothelial hypoxia and glycolysis-related gene signature, also observed in human kidneys with severe AKI. This metabolic program was coupled to upregulation of the SLC16A3 gene encoding the lactate exporter monocarboxylate transporter 4 (MCT4). Strikingly, treatment with the MCT4 inhibitor syrosingopine restored adaptive kidney repair in PHDTiEC mice. Mechanistically, MCT4 inhibition suppressed proinflammatory EC activation, reducing monocyte-EC interaction. Our findings suggest avenues for halting AKI to CKD transition based on selectively targeting the endothelial hypoxia-driven glycolysis/MCT4 axis.

22 December 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
GCGuillaume Courbon
Guillaume Courbon
DKDominik Kentrup
Dominik Kentrup
JTJane Joy Thomas
Jane Joy Thomas
XWXueyan Wang
Xueyan Wang
HTHao-Hsuan Tsai
Hao-Hsuan Tsai
AMAline Martin
Aline Martin
Fibroblast growth factor 23 (FGF23) is a phosphate-regulating (Pi-regulating) hormone produced by bone. Hereditary hypophosphatemic disorders are associated with FGF23 excess, impaired skeletal growth, and osteomalacia. Blocking FGF23 became an effective therapeutic strategy in X-linked hypophosphatemia, but testing remains limited in autosomal recessive hypophosphatemic rickets (ARHR). This study investigates the effects of Pi repletion and bone-specific deletion of Fgf23 on bone and mineral metabolism in the dentin matrix protein 1–knockout ( Dmp1 KO ) mouse model of ARHR. At 12 weeks, Dmp1 KO mice showed increased serum FGF23 and parathyroid hormone levels, hypophosphatemia, impaired growth, rickets, and osteomalacia. Six weeks of dietary Pi supplementation exacerbated FGF23 production, hyperparathyroidism, renal Pi excretion, and osteomalacia. In contrast, osteocyte-specific deletion of Fgf23 resulted in a partial correction of FGF23 excess, which was sufficient to fully restore serum Pi levels but only partially corrected the bone phenotype. In vitro, we show that FGF23 directly impaired osteoprogenitors’ differentiation and that DMP1 deficiency contributed to impaired mineralization independent of FGF23 or Pi levels. In conclusion, FGF23-induced hypophosphatemia is only partially responsible for the bone defects observed in Dmp1 KO mice. Our data suggest that combined DMP1 repletion and FGF23 blockade could effectively correct ARHR-associated mineral and bone disorders.

1 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MMMarta Martinez-Calle
Marta Martinez-Calle
GCGuillaume Courbon
Guillaume Courbon
BHBridget Hunt-Tobey
Bridget Hunt-Tobey
CFConnor Francis
Connor Francis
JSJadeah Spindler
Jadeah Spindler
VDValentin David
Valentin David
Renal osteodystrophy (ROD) is a disorder of bone metabolism that affects virtually all patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes including fractures, cardiovascular events, and death. In this study, we showed that hepatocyte nuclear factor 4α (HNF4α), a transcription factor mostly expressed in the liver, is also expressed in bone, and that osseous HNF4α expression was dramatically reduced in patients and mice with ROD. Osteoblast-specific deletion of Hnf4α resulted in impaired osteogenesis in cells and mice. Using multi-omics analyses of bones and cells lacking or overexpressing Hnf4α1 and Hnf4α2, we showed that HNF4α2 is the main osseous Hnf4α isoform that regulates osteogenesis, cell metabolism, and cell death. As a result, osteoblast-specific overexpression of Hnf4α2 prevented bone loss in mice with CKD. Our results showed that HNF4α2 is a transcriptional regulator of osteogenesis, implicated in the development of ROD.

21 April 2026 in Blood
Verified
Journal Article
Open access
PDF file
GCGuillaume Courbon
Guillaume Courbon
JTJane J. Thomas
Jane J. Thomas
EDEduardo Jorge Duque
Eduardo Jorge Duque
DKDominik Kentrup
Dominik Kentrup
JSJadeah Spindler
Jadeah Spindler
VDValentin David
Valentin David
Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone produced by osteocytes. In iron deficiency anemia (IDA) and in chronic kidney disease (CKD), FGF23 is also produced by erythroid cells. Recent studies have suggested that rising circulating FGF23 is negatively associated with erythropoiesis in IDA and CKD. However, the distinct contributions of bone- and erythroid-produced FGF23 to anemia in IDA remain unclear. Using the conditional deletion of Fgf23 in osteocytes (Fgf23Dmp1-cKO) and in erythroid cells (Fgf23HbB-cKO) in mice fed a control (Ctr) or an iron deficient (ID) diet, we first determined that in ID, osteocytes and erythroid cells are distinct sources of circulating intact FGF23 (iFGF23) and FGF23 cleaved peptides, respectively. We further show that erythroid-specific deletion of Fgf23 corrected anemia in ID mice, and overexpression induced anemia in Ctr mice unlike osteocyte-specific deletion or overexpression of Fgf23. Importantly, erythroid-specific deletion of Furin (FurinHbB-cKO), the enzyme responsible for FGF23 cleavage, led to increased production of iFGF23 from erythroid cells and aggravated ID-induced anemia. iFGF23 also dose-dependently blocked the differentiation of erythroid progenitors in culture triggering mitochondrial dysfunction leading to impaired erythropoiesis. These effects were fully suppressed by co-treatment with an FGFR1 inhibitor. Finally, erythroid-specific deletion of Fgf23 in an animal model of progressive CKD prevented the development of anemia of CKD. In aggregate, our results show that erythroid-expressed FGF23 is a negative regulator of erythropoiesis that contributes to anemia via direct paracrine FGFR1 activation in erythroid precursors.

6 October 2025 in Joint Bone Spine
Verified
Journal Article
Open access
ACAmélie Cifuentes
Amélie Cifuentes
ZLZacharie Laskar-Marchesseau
Zacharie Laskar-Marchesseau
GCGuillaume Courbon
Guillaume Courbon
The skeleton is able to secrete hormones and mediate endocrine functions. Particularly, the fibroblast growth factor 23 (FGF23) has received considerable attention for its unique phosphaturic properties, raising the bone to the status of an essential endocrine regulator. Excess in circulating levels of FGF23, not so surprisingly, then associated to mineral imbalance, in hereditary/acquired mineral and skeletal disorders. A key player, FGF23 excess precedes mineral and skeletal disturbances. However, unexpected effects have been described in the recent years. Various demonstrations have been made that FGF23 is directly regulated by non-mineral stress, including: inflammation, iron deficiency, and glycolysis. In turn, an emerging body of research shows association and causality between FGF23 and the cardiovascular system at large, from the iron metabolism to erythropoiesis, and to the cardiac muscle. This review summarizes canonical and novel effects of FGF23. FGF23 cleavage generates C-terminal peptides that also mediate biological functions. In aggregate, FGF23 measurements should be considered for larger application, as its excess can precede hypophosphatemia, explain hypophosphatemia or resistance to phosphate loading, and possibly predict cardiovascular progression in a wide range of uremic and non-uremic conditions.